Neuroblastoma Market Insights 2025-2034: Growth Dynamics, Trends, and Strategic Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What key factors are powering the surge in the neuroblastoma market right now?
In recent times, the neuroblastoma market has witnessed significant growth. The market value is expected to rise from $2.97 billion in 2024 to $3.15 billion in 2025, with a compound annual growth rate (CAGR) of 6.1%. The historical growth rate can be accredited to an increase in neuroblastoma cases, augmented research and development into pediatric neuroblastoma treatments, a rise in the occurrence of childhood cancer, and boosting support and funding from the government.
How fast Is the neuroblastoma market expected to grow, and what’s its future value?
In the forthcoming years, the neuroblastoma market is predicted to experience significant expansion, reaching a value of $3.93 billion in 2029, marking a compound annual growth rate (CAGR) of 5.7%. This advancement over the predicted period can be tied to factors like the escalation in government funding, prevalent increase in disease incidents, heightened emphasis on early diagnosis, growing occurrence of genetic abnormalities, and the amplification in knowledge and scientific progress. The forecast period will likely showcase key changes such as drug developments aimed at specific molecular pathways, breakthroughs in non-intrusive imaging technologies, advancements in gene editing technologies, a heightened emphasis on individualized treatments, and the creation of radiolabeled compounds.
Get your neuroblastoma market report here!
https://www.thebusinessresearchcompany.com/report/neuroblastoma–global-market-report
What are the leading drivers of growth in the neuroblastoma market?
Expected growth of the neuroblastoma market is thought to be propelled by a rise in childhood cancer rates. Childhood cancer is not a single disease, but a group of different cancers that often affect various organs such as the brain, blood and bones in children and adolescents that require distinct treatment modalities. An uptick in these instances owes much to enhanced diagnostics, heightened awareness, environmental exposures, genetic tendencies and progress in medical research. Neuroblastoma therapy gives specialised remedies targeted towards children’s cancer, promoting swift and effective interception, therefore reducing chances for cancer reappearance and promoting an enhanced prognosis for juvenile patients. Notably, in May 2024, the American Cancer Society revealed that around 9,620 children under 15 in the United States are expected to receive a cancer diagnosis in 2024, a significant jump from 5,290 cases in 2023. Consequently, this boost in cancer cases among children is fuelling the expansion of the neuroblastoma market.
What are the key segments defining the neuroblastoma market?
The neuroblastoma market covered in this report is segmented –
1) By Product Types: Tablets, Vaccines, Other Product Types
2) By Treatment Type: Chemotherapy, Immunotherapy, Other Treatment Types
3) By Distribution Channel: Online, Offline
4) By End-User: Hospitals, Clinics
Subsegments:
1) By Tablets: Oral Chemotherapy Tablets, Targeted Therapy Tablets
2) By Vaccines: Immunotherapy Vaccines, Therapeutic Vaccines
3) By Other Product Types: Injectable Drugs, Monoclonal Antibodies, Cell Therapy Products
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20901&type=smp
Who are the key players steering the development of the neuroblastoma market?
Major companies operating in the neuroblastoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Sartorius AG, Recordati S.p.A, United Therapeutics Corporation, BeiGene Ltd., MacroGenics Inc., Y-mAbs Therapeutics Inc., RedHill Biopharma Ltd., Clarity Pharmaceuticals Ltd., EUSA Pharma (UK) Ltd., US WorldMeds LLC, Healio Inc., Ascentage Pharma, Laboratorio Elea Phoenix S.A, Curis Inc., PersonGen BioTherapeutics (Suzhou) Co. Ltd., Essential Pharma S.A, Cellectar Biosciences Inc., Provectus Biopharmaceuticals Inc.
What key trends are currently impacting the neuroblastoma market’s development?
Major companies operating in the neuroblastoma market are focusing on developing advanced therapeutic interventions, such as humanized anti-GD2 monoclonal antibodies, to target and treat cancer cells more effectively and safely specifically. A humanized anti-GD2 monoclonal antibody is engineered to target the GD2 molecule on cancer cells with reduced immune rejection by incorporating human components. For instance, in August 2023, Renaissance Pharma Ltd., a UK-based clinical-stage pharmaceutical company, announced the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital. This antibody is designed to treat newly diagnosed high-risk neuroblastoma, a rare and aggressive childhood cancer. Under the terms of the agreement, Renaissance has secured exclusive rights to develop, manufacture, and commercialize Hu14.18 across key global markets, including the United States, Canada, Europe, China, Japan, and Turkey.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20901
Which regions are most influential in expanding the neuroblastoma market?
North America was the largest region in the neuroblastoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroblastoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Neurophysiology Devices And Equipment Global Market Report 2025
Neurostimulation Devices Global Market Report 2025
https://thebusinessresearchcompany.com/report/neurostimulation-devices-global-market-report
Neurodegenerative Disorder Therapeutics Global Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
